Archive for the Main Blog Category

LSVT Global Team Member Spotlight! Lorraine A. Ramig Ph.D., CCC-SLP, Chief Scientific Officer

Learn more about our LSVT Global Team member, Co-founder and Chief Scientific Officer, Lorraine Ramig, Ph.D., CCC-SLP. Her passion for improving communication and mobility for people with Parkinson’s and other disorders over the last 30+ years is the reason why this LSVT Global team exists today.

Continue Reading

LSVT BIG allowed my client to get to Hawaii for his 52nd anniversary trip!

Read Zach’s inspiring story on how LSVT BIG treatment allowed his client to take the anniversary trip of a lifetime!

Continue Reading

Increase your activity level with U-Step Neuro Walker & Urban Poling

Watch representatives from the U-Step Neuro Walker and Urban Poling show you how their innovative walking devices are designed to prevent falls, increase mobility and function, and improve participation in life’s activities.

Continue Reading

LSVT Global Partner Spotlight! FOX Rehabilitation

Learn more about our 8 year partnership with FOX Rehabilitation and how it has impacted their staff and the lives of the patients they treat. We here at LSVT Global are proud to collaborate with you!

Continue Reading

Want to Learn More About How to Apply LSVT Treatments Beyond Parkinson’s Disease?

Join LSVT LOUD and LSVT BIG Expert Clinicians as they discuss research studies and clinical cases on LSVT treatments applied to individuals with a diagnosis other than PD and how the clinical assessment can help determine if LSVT LOUD or LSVT BIG may be appropriate for select clients on your caseload.

Continue Reading

Tired of your device not understanding your speech? Sign up for Project Euphonia!

LSVT Global has partnered with Google on an exciting project called Project Euphonia to help improve automatic speech recognition software for people with speech impairments. These speech impairments may make using devices like Siri, Alexa, or speech-to-text frustrating. To do this, we need samples of disordered speech to train the system. LSVT Global is recruiting people with speech disorders to help!

Continue Reading

LSVT Global Team Member Spotlight! Jessica Galgano Ph.D., CCC-SLP

Learn more about our LSVT Global Team member Jessica Galgano, Ph.D., CCC-SLP. Jessica is an integral part of our team serving as LSVT LOUD faculty, LOUD for KIDS faculty and our LSVT LOUD clinical expert all while running her own successful private practice. Thank you, Jessica, for all you do for LSVT Global!

Continue Reading

The Acoustic Voice Quality Index (AVQI) in People with Parkinson’s Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial

This study presents the first randomized controlled trial (RCT) examining the effects of two speech treatment approaches, LSVT LOUD and LSVT ARTIC, on voice quality in individuals with Parkinson’s disease (PD). Both treatments were identical in how intensive they were, but LSVT LOUD targeted healthy loudness, whereas LSVT ARTIC focused on articulation. Additionally, an untreated group of individuals with PD also participated in the study, and a group of 20 individuals without PD were included to examine differences in voice quality at pre-treatment.

Continue Reading

LSVT Global Team Member Spotlight! Gary Boyle

Learn more about our LSVT Global Team member Gary Boyle who is one of our LSVT LOUD Volunteer Ambassadors. Gary is an inspiration to all of those around him with his compassion, positivity and eloquent words to share with faculty, fellow volunteers and LSVT clinicians in training. We are so fortunate to have you, Gary, as a part of our team. Thank you for the inspiration you give to us all!

Continue Reading

Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson’s disease dysphonia and the speech motor network: Randomized controlled trial

This study looked at speech and brain changes in individuals with Parkinson’s disease following two speech treatment approaches, matched for intensity of dosage (16, 1-hour individual sessions in one month) but differing on treatment target, loudness (LSVT LOUD) or articulation (LSVT ARTIC). A group of untreated individuals with Parkinson’s disease were also studied as a comparison group. All participants were evaluated at baseline, post-treatment (one month after baseline), and seven months after baseline to help identify both short-term and long-term changes.  

Continue Reading